IntroductIon
In the last few years, with the advent of transcatheter aortic valve implantation (TAVI), patients with symptomatic severe aortic stenosis, who previously had no treatment possibility due to contraindication or high surgical risk, began to have a treatment option. 1 Despite this new mode of intervention, these patients have high mortality at 2 years: 33.9% in high-risk cases and 43.3% in the inoperable. 2, 3 The Society of Thoracic Surgeons (STS) 4, 5 score and the European System for Cardiac Operative Risk Evaluation II (EuroSCORE II) 6 are used to help stratify surgical risk and the indication of TAVI. However, they have limitations due to the difficulty in differentiating highrisk patients from those in which the procedure can be considered unproductive, and also because they do not include numerous comorbidities that cause adverse surgical outcomes such as chronic obstructive pulmonary disease, liver cirrhosis, pulmonary hypertension, previous cardiac surgery, porcelain aorta, recurrent pulmonary embolism, right ventricular failure, contraindica-tion to open chest surgery (previous chest irradiation) or fragility. Thus, the role of risk scores as a predictive tool is questionable and there are no values to define patients not eligible for TAVI. [7] [8] [9] The objective of this study was to evaluate the performance of the EuroSCORE II and STS as predictors of in-hospital mortality and 30-day mortality in patients undergoing TAVI.
methodS
Single-center retrospective study that included 59 consecutive patients with severe aortic stenosis, defined in accordance with current guidelines, 10 symptomatic, who underwent TAVI in the period between 2010 and 2014. All cases were evaluated by a multidisciplinary team (Heart team) and underwent clinical assessment, electrocardiogram, chest X-ray, echocardiogram, multislice computed tomography of the aorta and branches, cine coronary angiography and laboratory tests. EuroSCORE II and STS scores were calculated using online tools (www.euroscore.org and riskcalc.sts.org/STSWebRiskCalc273). The procedure was performed in the cardiac catheterization lab or hybrid operating room under general anesthesia and with transesophageal echocardiography guidance. Medtronic CoreValve and Edwards Sapien heart valves were used. Complications and outcomes were defined according to the Valve Academic Research Consortium Consensus on Event Definition. 11 Fragility, characterized as poor physiological reserve, 13 was defined based on the index by Fried et al. 13 derived from the cohort of the Cardiovascular Health Study (CHS) with 5317 patients over 65 years, and includes items such as: weight loss, exhaustion, weakness, walking speed and reduced physical activity. Those with 3 or more criteria are considered fragile, adding risk of post-surgical complications, including mortality. 13 Continuous variables are presented as means ± standard error while categorical variables are shown as frequencies and percentages. The continuous variables were analyzed using unpaired Student's t-test, and the categorical variables using Fisher's exact test. Data normality was tested by Kolmogorov-Smirnov test. Discriminative power was assessed by receiver operating characteristic (ROC) curve and area under the curve (AUC), accompanied by 95% confidence interval. The test used for comparison of ROC curves was DeLong et al. 14 A p value <0.05 was considered statistically significant and the software used for the statistical analysis was MedCalc 15.4 (MedCalc Software bvba, Spain). This study was approved by the Research Ethics Committee.
reSultS

Population characteristics
Baseline characteristics are described in Table 1 . The average age was 81.0±7.3 years, 42.3% men. Etiology was degenerative in 96.61%, rheumatic in 1.69% and in 1.69%, bicuspid. The valve-in-valve procedure was performed in 8.47%. The average EuroSCORE II was 6.7±7.3% and STS 20.7±10.3%; 13.55% of patients had EuroSCORE II greater than 10%, while 91.5% had STS greater than 10%. The electrocardiographic evaluation shows atrioventricular conduction disorders in 15.2%, right bundle branch block in 6.7% and left bundle branch block in 6.7%. Echocardiography revealed a mean ejection fraction of 56±13.6%, mean aortic gradient of 47.5±16.7 mmHg and aortic valve area of 0.69±0.21 cm². Regarding laboratory tests, mean hemoglobin was 11.6±1.8 g/dL, serum creatinine 1.30±0.71 mg/dL and urea 60±29.2 mg/d. The average diameter of the valve annulus measured by computed tomography was 25.4±3.6 vs. 24.0±4.7 mm and the distances of the left and right coronary ostia were 13.4±2.6 mm and 14.1±3.1 mm, respectively. 
Outcomes
General in-hospital mortality was 10.1% and 30-day mortality was 13.5%, all related to the procedure (Table 2) . Two deaths (3.38%) occurred during the procedure due to cardiac tamponade. The remainder was caused by poor positioning of the prosthesis/thrombosis (1.69%), sepsis with worsening of heart function (3.38%), infective endocarditis with coronary embolization (1.69%) and aortic rupture (1.69%). None of the other deaths were witnessed. As for the transfemoral procedure alone, in-hospital mortality was 5.08% and 30-day mortality was 8.47%. In-hospital outcomes included stroke in 5.08%, major vascular complications in 8.47%, myocardial infarction in 1.69%, infective endocarditis in 5.08%, kidney injury in 23.7%, and need for permanent pacemaker implantation in 8.47%. In the latter, 10.8% used Medtronic CoreValve heart valves and 4.5% used Edwards Sapien valves.
Predictors
In the overall analysis, patients who died showed STS and EuroSCORE II significantly higher than the survivors (33.7±16.7 vs. 18.6±7.3 %; p= 0.0001 for STS and 13.9±16.1 vs. 4.8±3.8 %; p= 0.0007 for EuroSCORE II). In the ROC curve analysis, STS showed AUC at 0.81, while EuroSCORE II AUC was 0.77; no difference was found in discrimination ability using ROC (p=0.72) (Figure 1 ). Other clinical, laboratory and echocardiographic variables, as well as those related to the procedure, were analyzed and did not show statistical significance, except for left ventricular ejection fraction, higher in the patients who died (p=0.03) ( Table 3) . In the global univariate analysis, right bundle branch block was a predictor of permanent pacemaker (OR 24.0, RR 12.5; p=0,024). There was no association between type of cardiac prosthesis and need for pacemaker (p= 0.641).
dIScuSSIon
The risk scores currently used (EuroSCORE II & STS) were derived from databases of patients undergoing cardiac surgery. 15, 16 In addition, TAVI patients are usually elderly, with greater surgical risk and with numerous risk factors often not included in the current scores. [7] [8] [9] 15, 16 For these reasons, there is a need to identify predictors that help distinguish patients who may not benefit from the percutaneous procedure.
Data reported in the literature differ with respect to the mortality prediction ability of the EuroSCORE II and STS scores. While Stahli et al. 16 in a cohort of 350 patients and Sedaghat et al. 15 in a cohort of 206 patients demonstrated the superiority of EuroSCORE II, Hemmann et al. 17 in a record of 426 patients considered the STS superior. Other studies, as well as our work, demonstrated no difference between the scores, and, in our case, both the EuroSCORE II and STS scores had the ability to predict mortality, with AUC of 0.77 and 0.81, respectively. Since in our population the number of transaortic and transapical procedures was significantly lower than that of transfemoral procedures, preventing a comparative analysis, we chose to analyze the transfemoral procedure separately, and the findings were similar to the global analysis regarding mortality predictors.
In our study, STS overestimated the in-hospital and 30-day mortality rates, while the EuroSCORE II underestimated this outcome (Figure 2 ). One possible explanation for this finding is the fact that the STS score is composed of 40 clinical parameters for calculation, while the EuroSCORE II requires only 18. Despite that, in our study, STS score did not prove to be better able to predict mortality. 16 A finding in this study was that the left ventricular ejection fraction of patients who progressed to death was significantly higher than seen in the survivors (65.25±1.74% for death and 54.58±14.18 for survival; p=0.03). However, the average of the two groups was within the normal range and none of the witnessed deaths was due to cardiogenic shock.
Among the risk variables not included in the scores, fragility is a challenge for preoperative evaluation and causes significant impact on morbidity and postoperative mortality. 12, 13 It was observed in 52.5% of patients and in 75% of those who died, confirming its importance for indication of percutaneous procedure and its influence 
lImItatIonS
This is a single-center study with a small sample population. In addition, being a record, it has no power to assess the impact of prognostic tools.
concluSIon
In this cohort, among patients with severe aortic stenosis undergoing TAVI, STS and EuroSCORE II were predictors of in-hospital and 30-day mortality. In the absence of a risk score developed exclusively for this procedure, these scores can be useful as tools to aid clinical decision.
reSumo
EuroSCORE II e STS como preditores de mortalidade em pacientes submetidos ao TAVI Introdução: STS e EuroSCORE II são os escores mais utilizados para a estratificação de risco cirúrgico e indicação do implante de válvula aórtica transcateter (TAVI).
Entretanto, seu papel como ferramenta para predição de mortalidade em pacientes submetidos ao TAVI ainda é incerto. Objetivo: avaliar o desempenho do EuroSCORE II e STS como preditores de mortalidade intra-hospitalar em 30 dias em pacientes submetidos ao TAVI. Métodos: 59 pacientes com estenose aórtica importante submetidos ao TAVI entre 2010 e 2014. Variáveis foram analisadas por meio do teste t-Student e teste exato de Fisher, e o poder discriminativo foi avaliado pela curva ROC e área sob a curva, acompanhada de intervalo de confiança de 95%. Resultados: a idade média foi de 81±7,3 anos, 42,3% homens. Média do EuroSCORE II foi de 6,07±7,3%, e do STS, 20,7±10,3%. Procedimento transfemoral foi realizado em 88,13%, transapical, em 3,38% e transaórtico, em 8,47%. A mortalidade intra-hospitalar foi 10,1%, e em 30 dias, 13,5%. Os pacientes que evoluíram para óbito apresentavam STS e EuroSCORE II mais elevados que os sobreviventes (33,7±16,7% vs. 18,6±7,3%; p=0,0001 para STS e 13,9±16,1% vs. 4,8±3,8%; p=0,0007 para EuroSCORE II). O STS apresentou AUC de 0,81, e o EuroSCORE II, 0,77. Não houve diferença na capacidade de discriminação pelas curvas ROC (p=0,72). 
